NM-2201
- CA: Schedule II
- DE: Anlage II (Authorized trade only, not prescriptible)
- UK: Class B
- US: Schedule I
- Illegal in Sweden
- Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate
- 2042201-16-9 Y
- 91864534
- 30922478
- CCQ6IR3CU2
- DTXSID201009986
- Interactive image
- FCCCCCN1C=C(C(OC2=C(C=CC=C3)C3=CC=C2)=O)C4=CC=CC=C41
- InChI=1S/C24H22FNO2/c25-15-6-1-7-16-26-17-21(20-12-4-5-13-22(20)26)24(27)28-23-14-8-10-18-9-2-3-11-19(18)23/h2-5,8-14,17H,1,6-7,15-16H2
- Key:PRGFSQYZCKCBQO-UHFFFAOYSA-N
NM-2201 (also known as CBL-2201 and NA-5F-PIC[1]) is an indole-based synthetic cannabinoid that presumably has similar properties to the closely related 5F-PB-22 and NNE1, which are both full agonists and unselectively bind to CB1 and CB2 receptors with low nanomolar affinity.[2][3][4][5]
Pharmacology
NM-2201 acts as a full agonist with a binding affinity of 0.332 nM at CB1 and 0.732 nM at CB2 cannabinoid receptors.[6] It has been linked to serious adverse events in users.[7]
Legal status
NM-2201 is specifically banned in Sweden,[8] Germany (Anlage II),[9] and Japan[10] but is also controlled in many other jurisdictions under analogue laws.
On May 30, 2018 the United States Drug Enforcement Administration, Department of Justice published a notice of intent to place NM-2201 and 4 other synthetic cannabinoids in schedule I of the Controlled Substances Act. This notice went into effect on June 29, 2018.[11]
Use
NM-2201 was linked to an incident in December 2015 where 25-30 people in Ocala, FL were taken to hospitals after experiencing seizures.[11]
See also
References
- ^ Pulver, Benedikt; Fischmann, Svenja; Gallegos, Ana; Christie, Rachel (March 2023). "EMCDDA framework and practical guidance for naming synthetic cannabinoids". Drug Testing and Analysis. 15 (3): 255–276. doi:10.1002/dta.3403.
- ^ Kondrasenko AA, Goncharov EV, Dugaev KP, Rubaylo AI (December 2015). "CBL-2201. Report on a new designer drug: Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate". Forensic Science International. 257: 209–213. doi:10.1016/j.forsciint.2015.08.023. PMID 26386336.
- ^ "NM-2201". Cayman Chemical. Retrieved 9 July 2015.
- ^ Namera A, Kawamura M, Nakamoto A, Saito T, Nagao M (2015). "Comprehensive review of the detection methods for synthetic cannabinoids and cathinones". Forensic Toxicology. 33 (2): 175–194. doi:10.1007/s11419-015-0270-0. PMC 4525208. PMID 26257831.
- ^ Shevyrin V, Melkozerov V, Nevero A, Eltsov O, Baranovsky A, Shafran Y (November 2014). "Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data". Forensic Science International. 244: 263–75. doi:10.1016/j.forsciint.2014.09.013. PMID 25305529.
- ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
- ^ Samra K, Boon IS, Packer G, Jacob S (April 2017). "black mamba". BMJ Case Reports. 2017: bcr–2016–218431. doi:10.1136/bcr-2016-218431. PMC 5534782. PMID 28433979.
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. Retrieved 9 July 2015.
- ^ "Gesetz über den Verkehr mit Betäubungsmitteln Anlage II". www.gesetze-im-internet.de (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved 24 October 2016.
- ^ Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA (January 2017). "In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201)". Forensic Toxicology. 35 (1): 20–32. doi:10.1007/s11419-016-0326-9. PMC 5342258. PMID 28286577.
- ^ a b "2018 - Temporary Placement of NM2201, 5F-AB-PINACA, 4-CN-CUMYL-BUTINACA, MMB-CHMICA and 5F-CUMYL-P7AICA Into Schedule I". www.deadiversion.usdoj.gov. Retrieved 2018-06-15.
- v
- t
- e
(comparison)
Cannabibutols |
|
---|---|
Cannabichromenes | |
Cannabicyclols |
|
Cannabidiols | |
Cannabielsoins |
|
Cannabigerols | |
Cannabiphorols |
|
Cannabinols | |
Cannabitriols |
|
Cannabivarins |
|
Delta-8-tetrahydrocannabinols |
|
Delta-9-tetrahydrocannabinols | |
Delta-10-Tetrahydrocannabinols | |
Miscellaneous cannabinoids |
|
Active metabolites |
- Arachidonoyl ethanolamide (AEA; anandamide)
- 2-Arachidonoylglycerol (2-AG)
- 2-Arachidonyl glyceryl ether (2-AGE; noladin ether)
- 2-Oleoylglycerol (2-OG)
- N-Arachidonoyl dopamine (NADA)
- N-Arachidonylglycine (NAGly)
- 2-Arachidonoyl lysophosphatidylinositol (2-ALPI)
- N-Arachidonoyl serotonin (AA-5-HT)
- Docosatetraenoylethanolamide (DEA)
- Lysophosphatidylinositol (LPI)
- Oleamide
- Oleoylethanolamide (OEA)
- Palmitoylethanolamide (PEA)
- RVD-Hpα
- Stearoylethanolamide (SEA)
- O-Arachidonoyl ethanolamine (O-AEA; virodhamine)
cannabinoid
receptor
agonists /
neocannabinoids
Classical cannabinoids (dibenzopyrans) |
|
---|---|
Non-classical cannabinoids |
|
Adamantoylindoles |
|
Benzimidazoles | |
Benzoylindoles |
|
Cyclohexylphenols | |
Eicosanoids |
|
Hydrocarbons | |
Indazole carboxamides | |
Indazole-3- carboxamides |
|
Indole-3-carboxamides |
|
Indole-3-carboxylates | |
Naphthoylindazoles | |
Naphthoylindoles |
|
Naphthoylpyrroles | |
Naphthylmethylindenes | |
Naphthylmethylindoles | |
Phenylacetylindoles | |
Pyrazolecarboxamides |
|
Pyrrolobenzoxazines | |
Quinolinyl esters | |
Tetramethylcyclo- propanoylindazoles | |
Tetramethylcyclo- propanoylindoles | |
Tetramethylcyclo- propylindoles | |
Others |
|
enhancers
(inactivation inhibitors)
- 4-Nonylphenylboronic acid
- AM-404
- Arachidonoyl serotonin
- Arvanil
- BIA 10-2474
- Biochanin A
- CAY-10401
- CAY-10429
- Genistein
- Guineesine
- IDFP
- JNJ 1661010
- JNJ-42165279
- JZL184
- JZL195
- Kaempferol
- LY-2183240
- MK-4409
- O-1624
- O-2093
- Oleoylethanolamide (OEA)
- Olvanil
- Palmitoylethanolamide (PEA)
- PF-04457845
- PF-622
- PF-750
- PF-3845
- PHOP
- URB-447
- URB-597
- URB-602
- URB-754
- VDM-11
(antagonists/inverse
agonists/antibodies)
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- BML-190
- Brizantin (Бризантин)
- CAY-10508
- CB-25
- CB-52
- CB-86
- Dietressa (Диетресса)
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PipISB
- PSB-SB-487
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TM-38837
- VCHSR
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics